Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.

[1]  D. Martin,et al.  African Horse Sickness Caused by Genome Reassortment and Reversion to Virulence of Live, Attenuated Vaccine Viruses, South Africa, 2004–2014 , 2016, Emerging infectious diseases.

[2]  A. van Schalkwyk,et al.  Development of three triplex real-time reverse transcription PCR assays for the qualitative molecular typing of the nine serotypes of African horse sickness virus. , 2015, Journal of virological methods.

[3]  P. Kellam,et al.  Widespread Reassortment Shapes the Evolution and Epidemiology of Bluetongue Virus following European Invasion , 2015, PLoS pathogens.

[4]  P. Mertens,et al.  Genome Sequence of Bluetongue Virus Type 2 from India: Evidence for Reassortment between Outer Capsid Protein Genes , 2015, Genome Announcements.

[5]  S. Gubbins,et al.  Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge , 2015, Antiviral Research.

[6]  P. Roy,et al.  Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus , 2014, Vaccine.

[7]  S. Gubbins,et al.  Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge , 2014, Vaccine.

[8]  C. Batten,et al.  African horse sickness outbreaks caused by multiple virus types in Ethiopia. , 2014, Transboundary and emerging diseases.

[9]  S. Gubbins,et al.  Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation. , 2014, Virus research.

[10]  M. Carroll,et al.  Recombinant MVA vaccines: dispelling the myths. , 2013, Vaccine.

[11]  R. Lelli,et al.  Inactivated and adjuvanted vaccine for the control of the African horse sickness virus serotype 9 infection: evaluation of efficacy in horses and guinea-pig model. , 2013, Veterinaria italiana.

[12]  B. Sewell,et al.  Structural Insight into African Horsesickness Virus Infection , 2012, Journal of Virology.

[13]  E. Rossi,et al.  Immunogenicity of two adjuvant formulations of an inactivated African horse sickness vaccine in guinea-pigs and target animals. , 2012, Veterinaria italiana.

[14]  A. Firth,et al.  Detection of a Fourth Orbivirus Non-Structural Protein , 2011, PloS one.

[15]  R. Chiam,et al.  A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR −/− Mouse Model , 2011, PloS one.

[16]  B. Dungu,et al.  In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6. , 2010, Vaccine.

[17]  I. Gardner,et al.  Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. , 2009, Vaccine.

[18]  R. Chiam,et al.  Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA) , 2009, PloS one.

[19]  F. Monaco,et al.  African horse sickness: a description of outbreaks in Namibia. , 2009, Veterinaria italiana.

[20]  T. Smit,et al.  Evaluation of the pathogenicity of African Horsesickness (AHS) isolates in vaccinated animals. , 2008, Vaccine.

[21]  M. Jiménez-Clavero,et al.  Real-Time Fluorogenic Reverse Transcription Polymerase Chain Reaction Assay for Detection of African Horse Sickness Virus , 2008, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[22]  H. Attoui,et al.  Rapid cDNA synthesis and sequencing techniques for the genetic study of bluetongue and other dsRNA viruses. , 2007, Journal of virological methods.

[23]  G. Kärber,et al.  Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche , 1931, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[24]  B. Erasmus,et al.  Characterization of African horsesiekness virus , 2005, Archiv für die gesamte Virusforschung.

[25]  S. Gurunathan,et al.  Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors , 2004, Expert review of vaccines.

[26]  J. Sánchez-Vizcaíno.  Control and eradication of African horse sickness with vaccine. , 2004, Developments in biologicals.

[27]  A. A. van Dijk,et al.  The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant. , 2002, Vaccine.

[28]  M. Portas,et al.  African horse sickness in Portugal: a successful eradication programme , 1999, Epidemiology and Infection.

[29]  G. Viljoen,et al.  Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus. , 1999, The Onderstepoort journal of veterinary research.

[30]  P. Vogt,et al.  The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. , 1998, Virology.

[31]  P. Mellor,et al.  The Culicoides vectors of African horse sickness virus in Morocco: distribution and epidemiological implications. , 1998, Archives of virology. Supplementum.

[32]  D. Stuart,et al.  Structural studies of orbivirus particles. , 1998, Archives of virology. Supplementum.

[33]  P. Roy,et al.  New generation of African horse sickness virus vaccines based on structural and molecular studies of the virus particles. , 1998, Archives of virology. Supplementum.

[34]  P. Mellor,et al.  African Horse Sickness , 2022, Springer Vienna.

[35]  P. Roy,et al.  African horse sickness virus structure. , 1994, Comparative immunology, microbiology and infectious diseases.

[36]  C. Mebus,et al.  Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine. , 1994, Vaccine.

[37]  M. Castaño,et al.  African horse sickness in Spain. , 1992, Veterinary microbiology.

[38]  B. Moss,et al.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques , 1985, Molecular and cellular biology.

[39]  M. Jeggo,et al.  Clinical and serological response of sheep to serial challenge with different bluetongue virus types. , 1983, Research in veterinary science.

[40]  H. Huismans,et al.  On the relationship between bluetongue, African horsesickness and reoviruses: hybridization studies. , 1969, The Onderstepoort journal of veterinary research.

[41]  H. Mirchamsy,et al.  Inactivated African horse sickness virus cell culture vaccine. , 1968, Immunology.

[42]  Y. Ozawa,et al.  African horse-sickness killed-virus tissue culture vaccine. , 1966, Canadian journal of comparative medicine and veterinary science.

[43]  Erasmus Bj.  The attenuation of viscerotropic horsesickness virus in tissue culture. , 1965 .

[44]  P. G. Howell.  The isolation and identification of further antigenic types of African horsesickness virus , 1962 .

[45]  B. Mcintosh.  Immunological types of horsesickness virus and their significance in immunization , 1958 .